GENE17 LIMITED

Company Registration Number:
05939105 (England and Wales)

Unaudited abridged accounts for the year ended 30 September 2024

Period of accounts

Start date: 01 October 2023

End date: 30 September 2024

GENE17 LIMITED

Contents of the Financial Statements

for the Period Ended 30 September 2024

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

GENE17 LIMITED

Company Information

for the Period Ended 30 September 2024




Registered office: 20
Ivybridge
Tavistock Road
Weston-Super-Mare
BS22 6LP
Company Registration Number: 05939105 (England and Wales)

GENE17 LIMITED

Balance sheet

As at 30 September 2024


Notes

2024
£

2023
£
Fixed assets
Tangible assets: 4 5,835 6,235
Total fixed assets: 5,835 6,235
Current assets
Cash at bank and in hand: 7,354 2,175
Total current assets: 7,354 2,175
Creditors: amounts falling due within one year: ( 30,302 ) ( 22,718 )
Net current assets (liabilities): ( 22,948 ) ( 20,543 )
Total assets less current liabilities: ( 17,113 ) ( 14,308 )
Total net assets (liabilities): ( 17,113 ) ( 14,308 )

The notes form part of these financial statements

GENE17 LIMITED

Balance sheet continued

As at 30 September 2024


Notes

2024
£

2023
£
Capital and reserves
Called up share capital: 10 10
Profit and loss account: ( 17,123 ) ( 14,318 )
Shareholders funds: ( 17,113 ) ( 14,308 )

For the year ending 30 September 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 25 June 2025
And Signed On Behalf Of The Board By:

Name: Julie Westgarth
Status: Director

The notes form part of these financial statements

GENE17 LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

GENE17 LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

  • 2. Employees


    2024

    2023
    Average number of employees during the period 1 1

GENE17 LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

  • 3. Off balance sheet disclosure

    No

GENE17 LIMITED

Notes to the Financial Statements

for the Period Ended 30 September 2024

4. Tangible Assets

Total
Cost £
At 01 October 2023 91,695
Additions -
Disposals -
Revaluations -
Transfers -
At 30 September 2024 91,695
Depreciation
At 01 October 2023 85,460
Charge for year 400
On disposals -
Other adjustments -
At 30 September 2024 85,860
Net book value
At 30 September 2024 5,835
At 30 September 2023 6,235